pharmacology
DESCRIPTION
Hemantics and Hemostatics Sample TransTRANSCRIPT
Pharmacology 3.2 1st Sem/A.Y. 2015-2016
Hematinics, Hemostatics and Coagulants Glenn V. Guevara, MD September 11, 2015
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 1OF13
OUTLINE A. Introduction B. Anemia C. Iron Deficiency Anemia D. Hypoproliferative Anemia E. Megaloblastic Anemia F. Myelopoiesis G. Megakaryopoiesis H. Hemostasis I. Summary
HEMATINICS, HEMOSTATICS AND COAGULANTS
A. INTRODUCTION
A. Hematopoiesis
Figure 1: Hematopoiesis
Formation of blood components o Erythropoiesis: formation of RBCs o Myelopoiesis: formation of granulocytes and
monocytes o Megakaryopoiesis: formation of platelets
Derived from hematopoietic stem cells
B. Erythropoiesis
Figure 2: Erythropoiesis
Erythropoietin: main regulator of erythropoiesis o Stimulate hematopoietic stem cells from the bone
marrow to form RBCs o Released by kidneys in response to low O2 tension o Factors that decrease tissue oxygenation: low blood
pressure, anemia, low hemoglobin, poor blood flow, pulmonary disease
o Increased number of RBCs results to an increased O2 carrying capacity, inducing a negative feedback on EPO
Figure 3: Erythropoietin stimulation and inhibition
Iron: needed for maturation of red blood cells o Each RBC contains several hundred hemoglobin
molecules which transport oxygen o Iron is needed for the production of heme
Cobalamin
Folic Acid
B. ANEMIA
Decrease in the amount of RBCs or hemoglobin in the blood
Leads to lowered ability of blood to carry oxygen
Causes:
o Blood loss (most common cause): trauma, GI bleeding, abnormal menstrual bleeding
o Decreased RBC production Nutrient deficiency (iron, cobalamin, folic acid);
most common cause among decreased RBC production
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 2OF13
Thalessemia Bone marrow cancers Kidney disease Chronic infections Fluid overload- decrease in RBC production due to
volume expansion Increased RBC breakdown- Sickle Cell Disease
Types of Anemia
o By size: normocytic, macrocytic, microcytic o By color: normochromic, hypochromic, hyperchromic
Signs and Symptoms
Figure 4: Shows a somewhat good looking man with a creepy gaze. Also shown are the General Signs and Symptoms of Anemia. Diagnostic Tests
o Hemoglobin Count – hemoglobin concentration o Hematocrit - proportion of blood volume occupied by
RBC; also called "packed cell volume" or "erythrocyte
volume fraction" (about 3x the Hgb concentration) o RBC Count – number of RBC o Mean Corpuscular Volume (MCV)
Average volume or size of RBC MCV = (Hct x 10) / RBC number in million Normal MCV and decreased Hgb/Hct =
normocytic anemia; low MCV = microcytic and vice versa
o Mean Corpuscular Hemoglobin (MCH)
Average mass of hemoglobin per RBC in a sample of blood
Assess COLOR of the ANEMIA MCH = (Hgb x 10) / RBC number in million
o Mean Corpuscular Hemoglobin Concentration (MCHC)
Concentration of hemoglobin in a volume of packed RBC – the HUE OF RBC
MCHC = MCH/MCV x 100 This is more sensitive for measuring the actual
color because it considers both MCV and MCH o Blood Smear – morphology of RBCs
Table 1: Normal values for CBC
C. IRON DEFICIENCY ANEMIA
Most common cause of anemia
Due to increased iron demand, iron loss or decreased iron intake
More common in females (so take care and love your mom, sisters,
daughters and girlfriends, boys. There are a lot of illnesses associated with women.)
Microcytic and hypochromic
Causes:
Increased demand
o Growth and development – children, adolescents o Pregnancy
Blood loss
o Parasitic infections o Menorrhagia o Peptic ulcers o Patients on anticoagulants (aspirin, clopidogrel, etc)
Decreased intake
o Low iron diet: vegetarians, vegans o Malabsorption: intestinal resection, celiac disease,
inflammatory bowel disease, decreased acidity of stomach (due to prolonged proton pump inhibitor use, e.g. omeprazole)
A. Diagnostic Tests
(Why do we need to know this? Kinda boring but just see yourself as House,
Shepherd, Yang or Grey diagnosing your anemia patient. Wee!)
CBC (see diagnostic tests of anemia) Serum iron
It is the amount of circulating iron bound to transferrin
It can increase immediately on initiation of Fe supplementation
Serum ferritin
Most SENSITIVE indicator but is not reliable if within normal limits
Remember that ferritin is the storage form of iron
Hematocrit (Hct)
Male 45 %
Female 40 %
Hgb Count
Male 13.8 to 18.0 g/dl (8.56-11.17 mmol/L)
Female 12.1 to 15.1 g/dl (7.51-9.37 mmol/L)
Children 11-16 g/dL (6.83-9.93 mmol/L)
Pregnant 11-14 g/dL (6.83-9.93 mmol/L)
RBC Count
Male 4.7-6.1 millions/uL
Female 4.2-5.4 millions/uL
MCV 80-100 fl (femtoliters)
MCH 27-31 pg/cell (picograms)
MCHC 32-36 g/dL or 19.9-22.3 mmol/L
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 3OF13
Total Iron Binding Capacity (TIBC)
Most SPECIFIC indicator (when levels are high)
It measures the blood capacity to bind iron with transferrin. It is an indirect measure of transferrin
Transferrin is the transporter of iron in the blood. An increase would point to an increased need for iron (2017B)
It is usually elevated in IDA Transferrin Saturation Index (Percent Saturation/ Iron Saturation)
It is the percent saturation or iron saturation of transferrin
How much iron is currently bound to transferrin (2017B)
SI/TIBC x100
Table 2: Normal values
Serum Iron
Male 65-176 μg/dL
Female 50-170 μg/dL
Children 50-120 μg/dL
Newborn 100-250 μg/dL
Serum Ferritin
Male 18-270 ng/mL
Female 18-160 ng/mL
Children 7-140 ng/mL
Newborn 25-200 ng/mL
Total Iron Binding Capacity 240-450 μg/dL
Transferrin Saturation Index
Male >15-50%
Female >12-50%
Still Possible 5-10%
Definitely Abnormal <5%
Table 3: Differentiating microcytic anemia causes via lab tests. These are the different diseases that can present with microcytic anemia but focus your attention on IDA. There’s a lower serum iron, % saturation, and serum ferritin but a higher TIBC. If you order for a smear in IDA patients, you’d see a microcytic & hypochromic morphology.
Tests Iron Deficiency
Inflammation Thalassemia Sideroblastic
Smear Micro/hypo N/micro/hypo Micro/hypo w/ targeting
Variable
Serum Iron <30 <50 (N) to high (N) to high TIBC >360 <300 (N) (N) %saturation <10 10-20 (N) 30-80 30-80 Ferritin <15 30-200 (N) 50-300 50-300 Hemoglobin (N) (N) Abnormal (N)
Figure 5: Increasing severity of iron imbalance up to Iron Deficiency Anemia. Note the boxes in green, which indicate which stage would the first time the lab findings will appear (2017B). As the disease progresses, the other parameters that were normal become lower.
With a Negative Iron Balance, bone marrow iron stores,
serum ferritin decrease while TIBC increases.
With Iron Deficient Erythropoiesis, also SI, % saturation,
marrow sideroblasts decrease while RBC
protoporphyrin increases.
With IDA (which is severe), there is also morphological
change in the RBC
Figure 6: Hemoglobin Synthesis. Protoporphyrin IX is the step before heme. When it binds to iron, then there is the formation of heme. If there is an increase in protoporphyrin if there is no iron available in circulation. Thus no heme is formed. In severe forms of iron deficiency anemia, you see a lot of immature RBC in the blood. Thus, you’ll need iron supplementation to normal it out.
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 4OF13
B. Iron
In 1 mL of RBC, you will get 1 mg iron
Daily need: 15-20 mg/day (of elemental iron) due to 10-15% absorption of dietary iron o M: 1 mg/day o F: 1.5 mg/day o Higher requirement for:
Pregnant: 2-3x (5-6 mg) Children/adolescents: 1.5x
Vegetarian diet has 50% less iron absorption
High in Fe:
o red meat o egg yolk o dark leafy greens (spinach) o dried fruit (raisins, prunes) o iron enriched foods (cereals, grains) o mollusks (clams, oysters) o beans (soybeans)
Different forms of Iron:
Heme iron
o Red meat (Eww. Eat white meat to be healthy.) o absorbed directly through the heme transporter
FerrIc: IV supplement (e.g. Ferric Dextran)
o Why is it given parenterally? This is because it must be first converted to ferrous by duodenal cytochrome B (a
ferrireductase) to be absorbed in GIT.
FerrOus: Oral preparations (e.g. Ferrous gluconate)
o Why oral? Because it can be directly absorbed by the intestinal cell via DMT 1
Storage and Transport (Mentioned last year. From 2017 B)
Inside the intestinal cell, iron is stored as ferritin.
If iron is needed, it moves out as ferrous, becomes converted to ferric, and ferric binds to transferrin -> circulates in blood
Katzung: Ferritin is a B-globulin that can bind 2 molecules of ferric iron.
C. Management
Packed RBC Transfusion – for SEVERE ACUTE ANEMIA
o Usually secondary to blood loss o Supplementation can be started as adjunct but onset of
effects will be delayed
Oral iron
Parenteral iron
D. Oral Iron Preparations (Refer to Table 4)
What you need to memorize in the table is the elemental iron.
Remember that the supplement is often iron + a base salt (sulfate, fumarate). Sometimes they don’t show the elemental Fe in parenthesis and you have to compute from the dosage. (2017B)
Elixirs are available for children and for patients who cannot swallow.
Ferrous gluconate- given to children with iron deficiency anemia. It is usually prepared as an elixir
and combined with multivitamins.
Extended release has excipients to prolong release
(2017B)
Ferrous fumarate- usually combined with
multivitamins like folic acid and Vit-B complex
To reverse the anemia o You need to give iron supplementation for 3-
12 months. o In Harrisons, they suggested giving
300mg/day elemental iron but according to WHO, you can start with 60 mg/day elemental iron for patients with mild-moderate anemia.
o Eg. If a patient needs 60mg/day of elemental iron, you can give ferrous sulphate hydrated which has 65 mg. If you have a patient who needs 300mg/day of elemental iron, then you need to give 5 tablets of ferrous sulphate hydrated.
Benefits of Effective Iron Supplementation Programs (Mentioned last year. From 2017 B)
Children/adolescents o improved behavioral and cognitive development o improve child survival
Pregnant women and their infants: o decreased incidence of low birth weight babies
and perinatal mortality o decreased maternal mortality/obstetrical
complications
All individuals o improved fitness and work capacity o improved cognition
Table 4: Common Oral Iron Preparations
Generic Name Percent Elemental Iron
Tablet Elixir (5 ml)
Properties
Ferrous sulphate hydrated (dehydrate tetrahydrate)
20 % 325 (65)
300 (60)
Commonly given due to tolerability, effectiveness and low cost More of the GI irritation effect
195 (39)
90 (18)
Ferrous sulphate dessicated (monohydrate)
30-32%
Extended Release ferrous sulfate
20%
525 (105)
With incipients to prolong release
Ferrous fumarate
33 %
325 (107)
H% elemental iron; same effectiveness as sulfate
195 (64)
100 (33)
Ferrous bisglycinate
20% 75 (15) Iron amino acid chelate; good absorption & high
Remember: Fair (Fer) ROD and RICky B
ROD: FerRous, Oral, Direct, DMT 1
RICky B: FerRiC, IV, duodenal cytochrome B
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 5OF13
bioavailability
Ferrous gluconate
12% 325 (39)
300 (35)
Similar efficacy and tolerability as that of sulfate
Polysaccharide iron (eg. Maltose iron)
100% 150 (150)
100 (100)
Ferric complex with hydrolysed starch; less GI irritability;
E. WHO Guidelines of Iron Supplementation (from lecturer’s lecture slides)
The goal is to reverse anemia and provide 1g iron stores for up to 3-12 months.
Patients under iron supplementation have to be evaluated every month (2017)
Dosage: 60mg-300mg/day (300 is what Harrisons
recommends but for mild to moderate anemia, start at 60 mg)
Adults: 60 mg Pregnant: 60 mg iron/400 μg folic acid for 6 months of
pregnancy but may extend 3-6 months postpartum o Start supplementation at the SECOND
trimester (2017) o Higher toxicity in 1
st trimester (2017)
o Metallic taste exacerbates vomiting in the mother in 1
st trimester (2017)
Child 6-24 months: 12.5 mg iron/50 μg folic acid
(N 6-12 months; LBW <2500g 2-24 months)
Child 2-5 yrs: 20-30mg iron
Child 6-11 yrs: 30-60 mg
Adolescents and adults: 60 mg
Severe anemia o Child <2 yrs: 25 mg iron + 100-400 μg folic
acid x 3 months o Child 2-12: 60 mg iron+ 400 μg folic acid x 3
months o Adolescents, adults, pregnant women: 120
mg iron+ 400 μg folic acid x 3 months
F. Adverse Reactions & Precautions of Oral Iron
Oral iron may cause GIT distress in 15-20% of patients o Most common complaint which can decrease compliance
since treatment lasts for months o Abdominal pain, nausea, vomiting, constipation o You may switch to delayed release iron supplements
because they have less GIT adverse reactions
o This is often dose-related, another rationale to start low (Katzung)
Black stools are a side effect of oral iron. It has no
significant clinical effect except possible masking of gastrointestinal bleeding in fecalysis. (Katzung)
Taking the following with oral iron can DECREASE absorption: o milk, caffeine, antacids, calcium supplements
Vitamin C can INCREASE absorption. If you really need to reverse anemia immediately, then you can give your iron supplements with Vit C.
G. Response to Treatment
Reticulocyte count increases in 4-7 days after initiation of therapy and peaks at 1 ½ weeks
After 4 weeks of treatment, you need to see a Hemoglobin levels > 20g/dL. Thus first follow up is after 1 month.
Absence of response may be due to poor absorption, noncompliance to medication, or confounding diagnosis
Iron tolerance test –this is for adverse reactions and the response of a patient
o Give 2 iron tablets on an empty stomach o Serum iron in 2 hours: If increase is at least 100 μg/dL,
your treatment is adequate. H. Parenteral Iron Therapy Indicated for:
Poor tolerance to oral iron
Acute condition (blood loss) AS ADJUNCT to packed RBC
transfusion
Most common use: Large demand for iron from patients being treated with erythropoietin (which cannot be
satisfied by oral iron) especially hemodialysis patients or patients with kidney problems
Calculate the daily dose as follows:
Body Weight (kg) x 2.3 x (15 – px Hgb in g/dL) + 500 or 1000 mg (depending on target iron stores)
Two ways to administer
Administer total dose of iron required to correct deficit and provide at least 500 mg iron stores (can lead to more ADRs)
Give repeated small doses for certain period of time (most commonly used by doctors)
Forms of parenteral iron
Iron dextran o Contains 50 mg/mL elemental iron o Not being used anymore high risk of anaphylaxis
o Given <500mg IV/IM (half-life 6 hrs)
Sodium Ferric Gluconate, Iron Sucrose, Ferumoxytol – newer drugs o Given in chronic renal failure (CRF)
o IV ONLY (Katzung) o Ferritin levels between 500 and 1200 mg/mL and
transferrin saturations of <25% o Lower risk of anaphylaxis
Precautions (Katzung) (2017B)
Monitor iron storage levels via SI or TIBC.
Be careful in giving parenteral iron because overdose and toxicity can occur more easily as compared to the oral form. o So, it is important to properly calculate the daily dose
needed by the patient.
I. Iron Toxicity Acute
Exclusively in young children who swallow 10 tablets or
more
Effects include necrotizing gastroenteritis, vomiting, abdominal pain, bloody diarrhea, shock, lethargy, dyspnea, coma and death
Treatment includes: o Whole bowel irrigation o Deferoxamine (iron chelating compound) o Supportive therapy
o According to Katzung, it is useless to give activated charcoal because it does not bind iron.
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 6OF13
Chronic
Seen in patients given iron for a prolonged period of time at maximum dose
Usually there is hemochromatosis aka iron overload results
when there is excess iron deposition in heart, liver, pancreas etc
May be inherited or acquired (mostly acquired)
o Inherited hemochromatosis o B-thalassemia leading to repeated RBC transfusions
(Katzung)
Treatment includes the ff: o Intermittent phlebotomy (removes blood and therefore
excess iron; 1 unit/week) o Deferasirox: an oral iron chelator
According to Katzung, phlebotomy is what is usually done because iron chelators are more complicated, expensive, and hazardous. o It is only used as a last resort if a phlebotomy is not
enough.
D. HYPOPROLIFERATIVE ANEMIA
At least 75% of all cases of anemia are hypoproliferative in nature
A. Types and Diagnoses
Table 5: Diagnosis of Hypoproliferative Anemia
Iron Deficiency anemia
Most common type
Anemia of chronic disease
Caused by chronic inflammation (rheumatoid arthritis), TB, tissue injury, and cancer
Anemia of renal disease
Anemia results due to inadequacy of erythropoietin production secondary to impaired renal function
Examples are chronic renal failure (CRF), uremia, PCKD
Anemia of metabolic disease
Hypothyroidism and starvation
*Usual observation is that red cells are normocytic and normochromic
B. Endogenous erythropoietin
Produced in the kidney by intestinal fibroblasts; hypoxia stimulates its synthesis
Involved in erythropoiesis; stimulates progenitor proliferation and maturation
Involved in wound healing; it stimulates angiogenesis and smooth muscle fiber proliferation
Involved in the brain’s response to neuronal injury
Involved in vasocontriction-dependent hypertension
Increases iron absorption by suppressing hepicidin C. Recombinant Human Erythropoietin
Epoietin alfa or Darbopoietin alfa
Increase Hct by 4 points and Hgb by 1g/dL in 2 weeks
Darbopoietin alfa has a half-life 3-4x longer than that of
epoietin alfa; it is a second generation erythropoiesis-stimulating agent
Adverse effects known include, but are not limited to, allergic reactions, hypertension, migratory thrombophlebitis, microvascular thrombosis, pulmonary embolism, thrombosis of retinal artery, temporal veins, renal veins, headache, tachycardia, edema, shortness of breath, GI upset (nausea, vomiting, diarrhea), stinging sensation at injection site, flu-like symptoms
In light of this, iron supplementation and anticoagulants may be needed
Dosage for epoietin alfa (Guevarra, 2014):
o CRF: 50-150U/kg 3x/week IV or 80-120U/kg 1-3x/week IV /SQ (Hgb 10-12g/dL 4-6weeks; Hct 33-36% 2-4 months) ; maintained at 300U/kg
o AIDS: 100-300U/kg 3x/week IV/SQ o Cancer: 150U/kg 3x/week; can reached 450-600U/kg
1x/week o Surgery: 150-300U/kg OD for 10 days, day of surgery
and 4 days after surgery Dosage for darbopoietin alfa (Guevarra, 2014):
o CRF: 45µg/kg 1x/wk IV/SQ o Carries an increased risk of cancer recurrence.
E. MEGALOBLASTIC ANEMIA
Disorders characterized by presence of macrocytic red cells in bone marrow
Causes: O Cobalamin/folate deficiency O Abnormality (genetic/acquired) in cobalamin/folate
metabolism O DNA synthesis defects
Cobalamin
A water soluble vitamin containing a cobalt molecule
Plays a role in regulating normal function of CNS, blood formation, DNA synthesis, DNA regulation
Synthesized by microorganisms mainly
Coenzymes are methylcobalamin, a coenzyme involved
in methionine, S-adenosylmethionine, and tetrahyrofolate production, and adenosylcobalamin
Obtained via intake of fish, meat, dairy products
We obtain 5-30 µg via diet, we lose 1-3 µg per day, a store of 2-3 mg is good for 4 years
Passively absorbed in the buccal area, duodenum, and ileum; actively absorbed in the ileum in the presence of gastric intrinsic factor
Normal range is 150-600 pmol or 200-900 pg/ml Cobalamin deficiency can be caused by (Guevarra, 2014):
O Pernicious anemia due to IF loss secondary to atrophic gastritis
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 7OF13
O Inadequate amount of intake O Gastric and/or ileal resection O Decrease in gastric acid amount via proton pump
inhibitors and/or H2 blockers
O Alcoholism O Metformin intake O Malnutrition
Cobalamin deficiency results to (Guevarra, 2014):
O Topic in question, megaloblastic anemia O Progressive swelling of myelinated neurons O Demyelination O Neuronal cell death; these are seen in the spinal
column and cerebral cortex O Hand and foot paresthesia O Decrease in vibration and position sense, with
associated unsteadiness O Decrease in deep tendon reflexes O Confusion, moodiness, loss of memory O Loss of central vision
Vitamin B12 therapy (Guevarra, 2014)
O Given in cyanocobalamin and/or hydroxocobalamin, as these are the active medicinal forms
O If there is inadequate intake, give orally; if there is IF deficiency and/or gastric and ileal problems, give parenterally
O Cyanocobalamin is the first choice: give drug IM / SQ (not IV as there is a risk of anaphylaxis; skin test
needed), 1-1000µg 1-3x / week; supplementation is 80µg mixed w/ IF (not reliable; e.g. vegetarians)
O An alternative is hydroxocobalamin, given 100 µg
IM; this has a more sustained effect, lasting 3 months O Treatment usually lasts for 6-12 months, as a long
term treatment; cyanocobalamin is given monthly in the form of 100 µg injections
O Also given for cases of neuropathies such as
trigeminal neuralgia and multiple sclerosis, psychiatric disorders, poor growth and/or nutrition, as a tonic for patients suffering from tiredness and/or easy fatigue
Folic acid
Vitamin that is obtained from fresh green vegetables, fruits, liver, and yeast; 90% of vitamin is destroyed in the heat of cooking
Normally we obtain 50-500 µg of it per day; vegetarians only obtain roughly 2 mg/day
We usually require 400 µg per day; pregnant women require 500-600 µg per day; they must have an intake of at least 400 µg per day to prevent defects in the neural tube
Absorbed in duodenum and proximal jejunum (proximal small intestine), transported while bound to a plasma-binding protein
Normal range is 9-45 nmol or 4-20 ng/mL Deficiency (Guevarra, 2014)
O Causes are alcoholism, diseases of the proximal small intestine, inhibitors of dihydrofolate reductase such as methotrexate and trimethoprim, drugs that interfere in folate storage in tissues such as oral contraceptives
O Deficiency of folic acid can result to higher incidences of defects in the neural tube (anencephaly, encephaloceles, spina bifida), the topic in question (megaloblastic anemia), coronary artery and
peripheral vascular diseases, venous thrombosis or hyperhomocysteinemia
Therapy (Guevarra, 2014): O Given as folic acid, orally or parenterally or part of
MV prep O Given as a prophylaxis in pregnant women, (dose
of 400-500 µg per day); for hemolytic anemia it is given at a dose of 1 mg per day
O Can be given as folinic acid (leucovorin calcium), a
derivative of tetrahydrofolate O Folinic acid circumvents DHF reductase inhibition (ex.
Resulting from methotrexate intake); it is an antidote for folate antagonist toxicity (ex. Resulting from trimethoprim and pyrimethamine intake)
O Has no advantage over folic acid; it is actually more
expensive O Avoid multivitamin preparations; do multivitamin
preparations only if there is evidence of vitamin deficiency
O Folic acid is well tolerated by the body, even at doses as high as 15 mg per day
O Folic acid can decrease, even counteract effects of drugs like phenobarbital, phenytoin, primidone
F. MYELOPOIESIS
Myeloid growth factors are glycoproteins that stimulate the
proliferation and differentiation of one or more myeloid cell lines
Enhance the function of mature granulocytes and monocytes
Produced naturally by a number of different cells, including fibroblasts, endothelial cells, macrophages, and T cells
GM-CSF is capable of stimulating the proliferation,
differentiation, and function of a number of the myeloid cell lineages
G-CSF is restricted to neutrophils and their progenitors,
stimulating their proliferation, differentiation, and function
A. Conditions that affect Myelopoiesis
Autologous bone marrow transplantation
Intensive myelosuppressive cancer chemotheraphy
Zidovudine induced neutropenia in AIDS patients
Severe congenital neutropenia
B. Recombinant GM-CSF (Sargramostim)
Produced by yeast
125-500μg/m2
/d SQ (Half-life: 2-3hrs) [Katzung says: Serum T1/2 of 2-7 hours after IV or SQ administration
Slow infusion: 3-6 hours
Lower doses mainly affects neutrophils; larger doses affect monocytes/eosinophils
Adverse Effects: bone pain, malaise, flu-like symptoms, fever, diarrhea, dyspnea and rash, transient supraventricular arrhythmia, elevation of serum creatinine, bilirubin and hepatic enzymes
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 8OF13
C. Recombinant G-CSF (Filgrastim/Pegfilgrastim)
Filgrastim
o produced by Escherichia coli
o Stimulates CFU-G to increase neutrophil production; stimulation of CFU-G to increase
neutrophil production
o 1-20μg/kg/d IV infusion for 30 mins
o Patient on cancer chemotherapy: 5μg/kg/d; daily
administration for 14-21 days
Pelfigrastim
o gene through conjugation of a 20,000-Da
polyethylene glycol moiety to the G-CSF
glycoprotein produced by E. coli o Longer half-life o 6mg SQ
G. MEGAKARYOPOIESIS
Thrombopoietin, a cytokine that predominantly stimulates
megakaryopoiesis. It is produced by the liver, marrow stromal cells, and many other organs. It is the primary regulator of platelet production.
Interleukin-11 (IL-11) was cloned based on its activity to promote proliferation of an IL-6-dependent myeloma cell line Stimulates hematopoiesis, intestinal epithelial cell growth,
and osteoclasto-genesis and inhibits adipogenesis。Enhances megakaryocyte maturation in-vitro; in-vivo
increases peripheral blood platelet counts
Recombinant Interleukin-11 (Oprelvekin)
o Bacterially derived 19,000-Da polypeptide
o 25-50 μg/kg/d SQ; Half-life: 7 hours
o Administered daily; response in 5-9 days
o Used for chemotherapy induced thrombocytopenia in non-myeloid malignancies (20,000/μL). Aim:
platelet count reaches 100,000/μL
o Adverse Effects: Fluid retention and associated cardiac symptoms, such as tachycardia palpitation, edema, shortness of breath, blurred vision, injection site rash or erythema, and paresthesias.
Recombinant Thrombopoietin
o Recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) and Recombinant Human Thrombopoietin (rHuTPO) – mixed results on efficacy
o Mimics of recombinant thrombopoietin – used exclusively for ITP Romiplostim – small peptide that binds with high
affiity to the thrombopoietin receptor Safe and efficacious in patients with ITP Platelet ct >50,000/μL in 8 weeks of study 1-10 μg/kg/d SQ
Eltrombopag – 6 week course of 50-75mg/d
orally o Well-tolerated
H. HEMOSTASIS
A. Elements of Hemostasis
Primary Hemostasis
o Affected by: aspirin and NSAIDs o Adequate vascular response, platelets, levels of Von
Willebrand factor
Secondary Hemostasis
o Affected by: warfarin and heparin o Involve the extrinsic factors o Adequate level of clotting factors, vitamin K
B. Bleeding Disorders
Causes o Inherited coagulation disorders
clotting factor deficiency hemophilia
o Hemorrhagic diathesis of liver disease o surgical procedures / multi-organ injuries o vitamin K deficiency
C. Diagnostic Tests
platelet count: 150,000-400,000/m2
bleeding time (measure platelet function): 1-9 mins
prothrombin time (measure extrinsic pathway; used for warfarin): 11-13.5 sec
partial thromboplastin time (measure intrinsic pathway; used for heparin): 25-35sec
D. Vitamin K
cause of bleeding disorder
fat soluble
needed for complete synthesis of certain proteins that are required for blood coagulation (II, VII, IX, X) - 1972
also used to manipulate binding of calcium in bone and other tissues
RDI
Infants: 10–20μg/day
Children & adolescents: 15–100μg/day
Males: 120 μg/day
Females: 90 μg/day (lower than males) Vitamin K Deficiency
o Uncommon o Causes:
Resection of SI Malabsorption syndrome Prolonged use of broad spectrum antibiotics Diet low in vit. K CKD Alcoholics Liver disease Anticoagulants Salicylates Barbiturates Cefamandole
o Usually occurs in newborns right after birth clotting factors are 30 to 60% of adult values due to reduced synthesis of precursor proteins and
the sterility of their guts
Vit. K deficiency bleeding in 1st
week of the infant's life is 0.25 to 1.7%
given especially in premature babies
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 9OF13
F. Tissue Plasminogen Activator (TPA) Inhibitors
Used to control bleeding in patients
Seen in the final stage of thrombin formation
Inhibitors of fibrinolysis
Plasmin has a role in the lysis of clot made by secondary hemostasis
Aminocaproic acid
Competes for lysine binding sites on plasminogen and plasmin, blocking the interaction of plasmin with fibrin
A very potent inhibitor of fibrinolysis (thrombi that formed during treatment with the drug are not lysed)
Used to reduce bleeding after prostatic surgery or after tooth extractions in haemophiliacs
also used to prevent bleeding after surgical procedures (ability to treat a variety of bleeding disorders has been unsuccessful)
Loading dose: 4-5g IV/PO during the 1st hour then 1-1.25g
PO q1Hour ; continuous IV infusion at 1g/Hr (continue for 8 hours or until bleeding is controlled, not to exceed 30g/day)
Tranexamic acid
Like aminocaproic acid, competes for lysine binding sites on plasminogen and plasmin, thus blocking their interaction with fibrin
Safer than aminocaproic acid
Can be used for the same indications as aminocaproic
acid and can be given IV or orally Usually given 1g 4x/day for 4 days (500mg 3x/day for 4-7days)
*Adverse effects of both drugs: hypersensitivity reactions,
nausea, vomiting, diarrhea, clotting problems (loss of vision, infarct, embolism)
I. SUMMARY
Erythropoietin stimulates erythropoiesis. (without it there will be no erythropoiesis that will happen)
Iron is needed for maturation of RBC.
Defective RBCs are formed in patients with Vit. B12 and B9 are deficient.
GM-CSF, G-CSF, IL-11 and thrombopoietin are helpful in certain conditions that produce neutropenia or thrombocytopenia
Vit. K supplementation can be given to patients with certain bleeding disirders.
TPA inh. can be given to patients suffering bleeding from trauma, surgery, etc.
GUIDE QUESTIONS 1. All of the following substances delay absorption of ingested iron EXCEPT:
A. caffeine B. milk C. sodium ascorbate D. calcium ascorbate 2. Which of the following parenteral iron preparations has a higher incidence of anaphylactic reactions?
A. ferric gluconate B. ferric sucrose C. ferric dextran D. ferric oxide 3.Lexi, a 32-year-old female, diagnosed with iron deficiency anemia, needs 60mg a day of elemental iron. To minimize the incidence of adverse reactions, you decided on a “once
a day” dosing regimen for the patient. Which of the following drugs will be best suited for the patient? A. ferric-maltose complex 150 mg B. ferrous sulfate dessicated 325 mg C. ferrous fumarate 200mg D. ferrous gluconate200 mg 4. Which of the following iron preparations is usually found in multivitamin medicated syrups because of its low elemental iron content?
A. ferrous gluconate B. ferrous sulfate dessicated C. ferrous fumarate D. ferric-maltose complex 5. Which of the following conditions associated with cobalamin deficiency will benefit most from oral cyanocobalamin?
A. atrophic gastritis B. inflammatory bowel disease C. chronic alcoholism D. ileal resection 6. The conditions that will least likely benefit from epoeitin alfa treatment
A. massive traumatic blood loss B. chronic renal failure C. cancer D. AIDS 57. Which of the following will most likely happen when correcting cobalamin deficiency with folic acid supplementation?
A. lower incidence of homocysteinemia and venous thrombosis B. lower incidence of megaloblastic anemia C. decreased risk for nerve degeneration D. increased risk for neural tube defects 8. In a patient with neutropenia, which of the following agents will be least beneficial?
A. sargamostim B. Romiplostim C. filgrastim D. perfilgrastim 9. Thrombocytopenia from immunosuppressive chemotherapy can be treated with the following medications EXCEPT:
A. elthrombopag B. romiplostim C. sargramostim D. Oprelvekin 10. Which of the following available vitamin K preparations is toxic for humans? A. phylloquinone B. menaquinone C. menatetrenone D. menadione
Answers: 1)C 2)C 3)C 4)A 5)C 6)A 7)B 8)B 9)C 10)D
OBJECTIVES None.
REFERENCES 1. Dr. Guevarra’s Lecture 2. Katzung 3. 2017B trans
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 11OF13
APPENDIX
Table 6: Vitamin K1 vs. Vitamin K2
Vitamin K1 Vitamin K2
Form Phylloquinone, Phytomenadione, Phytonadione,
Menaquinones, Bacteria in SI can convert vit .K1 to K2
Source Leafy green vegetables: dandelion greens, spinach, lettuce, cabbage, cauliflower, broccoli, and brussels sprouts Fruits: avocado, kiwifruit and grapes
Animal Meat: chicken, beef, their fat, livers, and organs Fermented or aged cheese, eggs Bacteria in SI can convert K1 to K2
Absorption Small intestine Small intestine
Signs and Symptoms of Deficiency
Anemia, bruising, bleeding gum or nose, heavy menstrual bleeding
Deficiency Osteoporosis, Coronary heart disease, Severe aortic calcification
Therapy At birth:
IV: 0.5 to 1.0 mg Newborns:
Human milk (1–4 μg/L)
Vit. K formula-derived milk (100 μg/L)
Menopausal women:
Orally (45 mg daily)
To prevent osteoporosis Rapid reversal from warfarin for pre-op:
Orally (1-2.5 mg)
Figure 1: Events in Hemostasis
Pharmacology 3.02
2018-A DOMONDON, DUENAS, DUNGO, ENCARNACION, ENRIQUEZ 12OF13
Figure 2: Factors that favor and inhibit thrombosis
Figure 3: Myelopoiesis